SecBot SecBot
8-K ·Filed Feb 24, 2026

LAB

STANDARD BIOTOOLS INC.
BEARISH
Impact 7/10
Horizonweeks Processed8mo ago SEC0001193125-26-067026
8-K Item 2.02: Earnings release
Actionable Insight ▼ Bearish

The stock may react negatively to the continued revenue decline and weak guidance, despite the improved net loss. The one-time tax benefit masks underlying operational weakness. Traders should watch for further signs of deterioration in the core business and whether the company can achieve profitability with its reduced scale.

DirectionBearish
Confidencehigh
Horizonweeks

How the stock moved after the report

BEARISH VIEWSTOCK BELOW ENTRY AT T+60
Entry
$1.17
T+0 close · Feb 24, 2026 · via day close
Latest settled
−9.40%
T+60 · $1.06
Vs SPY
−16.35%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Feb 25 $1.17entry
  2. T+1 · 9mo ago 0.00%α +0.55% · $1.17
  3. T+5 · 9mo ago −9.40%α −8.30% · $1.06
  4. T+20 · 8mo ago −17.95%α −12.71% · $0.9600
  5. T+60 · 6mo ago −9.40%α −16.35% · $1.06
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Standard BioTools reported FY2025 revenue of $85.3 million, down 6% YoY, with Q4 revenue of $23.8 million, down 4% YoY. While net loss improved to $58.8 million (from $90.9 million) due to a one-time $38.4 million tax benefit, core operating performance declined. The company expects FY2026 revenue of $80-$85 million, signaling continued contraction. Despite $550 million in cash from the SomaLogic sale, the fundamental business is weakening.

Key Financial Metrics

Revenue
$85.3M
-6.0% YoY
EPS
$-0.15
Guidance
$80M-$85M
lowered
Gross Margin
49.9%

Key Facts

  • FY2025 revenue was $85.3 million, down 6% YoY; Q4 revenue was $23.8 million, down 4% YoY
  • FY2025 net loss improved to $58.8 million from $90.9 million in 2024, but this was primarily due to a one-time $38.4 million tax benefit, not operational improvement
  • Adjusted EBITDA loss was $62.6 million in 2025, only a 3% improvement from $64.2 million in 2024
  • The company guided FY2026 revenue to $80-$85 million, indicating an expectation of continued revenue decline
  • Consumables revenue fell 11% YoY in 2025, while instruments grew only 2% YoY, indicating weak core demand
  • The company has $550 million in cash from the SomaLogic sale but is not profitable and expects revenue to decline further

Financial Impact

Revenue declined 6% YoY to $85.3 million, with a net loss of $58.8 million. FY2026 revenue is expected to decline further to $80-$85 million.

revenueepsnet incomeguidance

Segment Breakdown

SegmentRevenueGrowth
Instruments$25.4M+2.0%
Consumables$36.2M-11.0%
Services$23.7M-7.0%

Risk Factors

  • Continued revenue decline in core business
  • Failure to achieve profitability despite cost-cutting
  • Dilution risk from potential M&A activity using the cash balance
  • Weak guidance suggests further contraction in 2026

Market Snapshot

Exchange
Nasdaq

Investment Themes

Industrials & Manufacturing

Documents Analyzed

This report is based on 5 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001193125-26-067026
Document: lab-20260224.htm0001193125-26-067026
Document: 0001193125-26-067026-index-headers.html0001193125-26-067026
Document: 0001193125-26-067026-index.html0001193125-26-067026
Document: 0001193125-26-067026.txt0001193125-26-067026

Track record

23 reports on LAB

Performance horizon

7 of 8 bullish or bearish reports moved the stock their way by T+1. Best: +10.47% at T+20 after the Jun 8, 2026 report. 8 of 8 went positive at some point.

Filters
  1. Nov 16, 2026today 425 Neutral 4/10 Entry price pending
  2. Nov 16, 2026today 8-K Neutral 3/10 Entry price pending
  3. Nov 3, 202613d ago 425 Neutral 3/10 Entry $0.6108 to $0.6160 Now $0.6200 +1.51% ▲ +0.85% −0.80% vs SPY
  4. Nov 3, 202613d ago 8-K Neutral 4/10 Entry $0.6108 to $0.6160 Now $0.6200 +1.51% ▲ +0.85% −0.80% vs SPY
  5. Nov 3, 202613d ago Press Release Neutral 3/10 Entry $0.6108 to $0.6160 Now $0.6200 +1.51% ▲ +0.85% −0.80% vs SPY
  6. Oct 22, 202626d ago EFFECT Neutral 4/10 Entry $0.6400 to $0.6056 Now $0.6200 −3.12% ▼ −5.38% −4.85% vs SPY
  7. Oct 21, 202626d ago S-4/A Bearish 7/10 Entry $0.6500 to $0.6400 Now $0.6200 +4.62% ▲ +1.54% +0.36% vs SPY
  8. Oct 9, 20265w ago S-4/A Neutral 6/10 Entry $0.6578 to $0.6589 Now $0.6200 −5.75% ▲ +0.17% +0.18% vs SPY
  9. Oct 5, 20266w ago 425 Neutral 5/10 Entry $0.7220 to $0.6787 Now $0.6200 −14.13% ▼ −6.00% −5.76% vs SPY
  10. Oct 5, 20266w ago 8-K Neutral 4/10 Entry $0.7220 to $0.6787 Now $0.6200 −14.13% ▼ −6.00% −5.76% vs SPY
Showing 10 of 23

US Market Status

Market Closed · Opens Wed (9h 49m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Feb 24, 2026